dermatomyositis (CADM) and a poor prognosis due to rapidly progressive interstitial lung disease (RP-ILD). Recently, combination protocol involving high-dose PSL and biweekly IVCY with a calcineurin inhibitor in RP-ILD was described. However, there are many unclear points in the clinical course in the combination therapy.
ILD. All patients with RP-ILD were treated with combination protocol and 2 patients were needed to add with rituximab. 6 patients were dead by current disease. There was a tendency of the elderly and high A-aDO2 at the admission in patients who died. Laboratory and image dates weren't different. The incidence of mediastinal emphysema and bacterial, fungal, or cytomegalovirus (CMV) infection was complicated during treatments.
Conclusion: Combination protocol was effective in patients with RP-ILD. In clinical phenotypes, age and A-aDO2 were only significantly related to the response to therapy. 2 patients, Nonspecific Interstitial Pneumonia (NSIP) 2 patients and Organizing Pneumonia (OP) 1 patient. Treatment regimen were Methylprednisolone (mPSL) pulse + Intravenous cyclophosphamide (CYC) + tacrolimus + intravenous immunoglobulin (IVIG) 3 patients, mPSL pulse+Intravenous CYC + tacrolimus 1 patient, mPSL pulse+tacrolimus 1 patient. 4 patients died within 2 months after treatment, and 3 patients had Ulceration all patients were started treatment after 2 months or more from any symptoms appeared. Only one patient(Female) alive. She had no Ulceration and was started treatment within 12 days from symptoms appeared, and low serum ferritin and neutrophil/lymphocyte ratio (NLR).
Conclusion:
Four of five patients died within 2 months after treatment with poor prognosis. We report about prognosis factor of this disease from previous reports. Methods: Clinical data were retrospectively analyzed in 85 patients with SSc-ILD (biopsy proven case, n = 17). The Cox proportional hazards regression model was used for analyzing predictors for clinical outcomes.
Results: Median follow-up period was 4.6 years (interquartile range: 2.7-7.4 years). Mean age of the subjects was 53 years, 15% were male, and 21% were smokers. The overall mortality rate was 12.9% during follow-up (1 year = 0%, 3 years = 4.7%, 5 years = 5.9%). Non-survivors showed shorter duration of dyspnea (0.9 years vs 2.1 years., P = 0.006) and lower diffusing capacity of carbon monoxide (49.3 AE 23.1 % predicted. vs 60.5 AE 18.7 % predicted. , P = 0.089) compared with survivors; however, there were no significant differences in other variables including age, sex, smoking history and exercise capacity ( 
